CD38 and Interleukin 6 Gene Polymorphism in Egyptians with Diffuse Large B-Cell Lymphoma (DLBCL)

References

• Abramenko IV, Bilous NI, Pleskach GV, et al. (2012). CD38 gene polymorphism and risk of chronic lymphocytic leukemia. Leuk Res, 36, 1237–40
   PubMed Web of Science ®Google Scholar
• Albeniz I, Demir-Coşkun O, Türker-Şener L, et al. (2011). CD38 expression as response of hematopoietic system to cancer. Oncol Lett, 2, 659–64
   PubMed Web of Science ®Google Scholar
• Ausiello CM, la Sala A, Ramoni C, et al. (1996). Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Cell Immunol, 173, 192–7
   PubMed Web of Science ®Google Scholar
• Ausiello CM, Urbani F, la Sala A, et al. (1995). CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur J Immunol, 25, 1477–80
   PubMed Web of Science ®Google Scholar
• Aydin F, Yilmaz M, Ozdemir F, et al. (2002). Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin’s lymphoma. Am J Clin Oncol, 25, 570–2
   PubMed Web of Science ®Google Scholar
• Aydin S, Rossi D, Bergui L, et al. (2008). CD38 gene polymorphism and chronic lymphocytic leukemia: A role in transformation to Richter syndrome? Blood, 111, 5646–53
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. (2011). The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 12;117, 5019--32
   Google Scholar
• Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. (2008). Genetic variation in tumor necrosis factor and the nuclear factor-KB canonical pathway and risk of Non-Hodgkin’s Lymphoma. Cancer Epidemiol Biomarkers, 17, 3161–9
   PubMed Web of Science ®Google Scholar
• Deaglio S, Aydin S, Grand MM, et al. (2010). CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med, 16, 87–91
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Bergui L, et al. (2005). CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood, 105, 3042–50
   PubMed Web of Science ®Google Scholar
• El-Far M, Fouda M, Yahya R, et al. (2004). Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem, 60, 253–8
   PubMed Web of Science ®Google Scholar
• Emilie D, Devergne O, Raphael M, et al. (1992). Production of interleukin-6 in high-grade B lymphomas. Curr Top Microbiol Immunol, 182, 349–55
   PubMedGoogle Scholar
• Fabre-Guillevin E, Tabrizi R, Coulon V, et al. (2006). Aggressive non-Hodgkin’s Lymphoma: Concomitan evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma, 47, 603–11
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating MJ, Reuben JM, et al. (2001). Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia correlation with phenotypic characteristics and outcome. Blood, 97, 256–63
   PubMed Web of Science ®Google Scholar
• Ferrero E, Malavasi F. (1997). Human Cd38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotyic gene family of Nicotinamide Adenine Dinucleotide 1–converting enzymes. J Immunol, 159, 3858–65
   PubMed Web of Science ®Google Scholar
• Ferrero E, Saccucci F, Malavasi F. (1999). The human CD38 gene: Polymorphism, CpG island, and link-age to the CD157 (BST-1) gene. Immunogenetics, 49, 597–604
   PubMed Web of Science ®Google Scholar
• Ferrero E, Saccucci F, Malavasi F. (2000). The making of a leukocyte receptor: Origin, genes and regulation of human CD38 and related molecules. Chem Immunol, 75, 1–19
   PubMedGoogle Scholar
• Fishman D, Faulds G, Jeffery R, et al. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest, 102, 1369–76
   PubMed Web of Science ®Google Scholar
• Gregorini A, Tomasetti M, Cinti C, et al. (2006). CD38 expression enhances sensitivity of lymphoma T and B cell lines to biochemical and receptor-mediated apoptosis. Cell Biol Int, 30, 727–32
   Google Scholar
• Guney N, Soydinc HO, Basaran M, et al. (2009). Serum Levels of Interleukin-6 and Interleukin-10 in Turkish Patients with Aggressive Non-Hodgkin’s Lymphoma. Asian Pac J. Cancer Prev, 10, 669–674
   Google Scholar
• Hartman WR, Pelleymounter LL, Moon I, et al. (2010). CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. Leuk Lymphoma, 51, 1315–1325
   PubMed Web of Science ®Google Scholar
• Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. (2002). A comprehensive review of genetic association studies. Genet Med, 4, 45–61
   PubMed Web of Science ®Google Scholar
• Horikawa M, Minard-Colin V, Matsushita T, Tedde TF. (2011). Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest, 121, 4268–80
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Pertovaara M, Antonen J, et al. (2001). Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestations of the disease. Rheumatology, 40, 656–61
   PubMed Web of Science ®Google Scholar
• Iqbal J, Zaidi M. (2007). CD38 is required for priming by TNF-α: A mechanism for extracellular coordination of cell fate. Am J Physiol Renal Physiol, 292, 1283–90
   PubMed Web of Science ®Google Scholar
• Jackson DG, Bell JI. (1990). Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol, 144, 2811–15
   PubMed Web of Science ®Google Scholar
• Jaffe ES. (2009). The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program, 523–31
   PubMedGoogle Scholar
• Jamroziak K, Szemraj Z, Grzybowska-Izydorczyk O, et al. (2009). CD38 Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. J. Cancer Epidemiol Biomarkers Prev, 18, 945–53
   PubMed Web of Science ®Google Scholar
• Kallen KJ. (2002). The role of trans-signaling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta, 1592, 323–43
   PubMed Web of Science ®Google Scholar
• Kishimoto H, Hoshino S, Ohori M, et al. (1998). Molecular mechanism of human Cd38 gene expression by retinoic acid-identification of retinoic acid response element in the first intron. J. Biol Chem, 273, 15429–34
   PubMed Web of Science ®Google Scholar
• Kube D, Hua TD, von Bonin F, et al. (2008). Effect of Interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive Non-Hodgkin’s lymphoma: An exploratory study. Clin Cancer Res, 12, 3777–84
   Web of Science ®Google Scholar
• Kurzrock R, Redman J, Cabanillas F, et al. (1993). Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res, 53, 2118–22
   PubMed Web of Science ®Google Scholar
• Lande R, Urbani F, Di Carlo B, et al. (2002). CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, IL-10 secretion in resting human monocytes. Cell Immunol, 220, 30–8
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E, Baseggio L, Bienvenu J, et al. (2004). Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood, 103, 3529–34
   PubMed Web of Science ®Google Scholar
• Liu RY, Song X, Chen P, et al. (2012). Association between IL6 −174G/C and cancer: A meta-analysis of 105,482 individuals. Exp Ther Med, 3, 655–64
   Google Scholar
• Malavasi F, Deaglio S, Funaro A, et al. (2008). Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. Physiol Rev, 88, 841–86
   PubMed Web of Science ®Google Scholar
• McNally GA. (2011). B-cell lymphoma, unclassifiable. Clin J Oncol Nurs, 15, 189–93
   Google Scholar
• Morozumi T, Sharma A, De Nardin E. (2009). The functional effects of the −455G/A polymorphism on the IL-6-induced expression of the beta-fibrinogen gene may be due to linkage disequilibrium with other functional polymorphisms. Immunol Invest, 38, 311–23
   PubMed Web of Science ®Google Scholar
• Nachbaur DM, Herold M, Maneschg A, Huber H. (1991). Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters. Ann Hematol, 62, 54–8
   PubMed Web of Science ®Google Scholar
• Nakagawara K, Mori M, Takasawa S, et al. (1995). Assignment of CD38, the gene encoding human leukocyte antigen CD38 (ADP-ribosyl cyclase/ cyclic ADP-ribose hydrolase), to chromosome4p15. Cytogenet Cell Genet, 69, 38–9
   PubMedGoogle Scholar
• Nakamura N, Abe M. (2003). Richter syndrome in B-cell chronic lymphocytic leukemia. Pathol Int, 53, 195–203
   PubMed Web of Science ®Google Scholar
• Nata K, Takamura T, Karasawa T, et al. (1997). Human gene encoding Cd38 (Adp-Ribosyl Cyclase/Cyclic Adp-Ribose Hydrolase): Organisation, nucleotide sequence and alternative splicing. Gene, 186, 285–92
   PubMed Web of Science ®Google Scholar
• Oluwasola AO, Olaniyi JA, Otegbayo JA. (2011). Fifteen-year review of lymphomas in a Nigerian tertiary healthcare. J Health Popul Nutr, 29, 311–16
   Google Scholar
• Rothman N, Skibola CF, Wang SS, et al. (2006). Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the Inter- Lymph Consortium. Lancet Oncol, 7, 27–38
   PubMed Web of Science ®Google Scholar
• Rust S, Funke H, Assmann G. (1993). Mutagenically separated PCR (MS-PCR): A highly specific one step procedure for easy mutation detection. Nucl Acids Res, 21, 3623–9
   PubMed Web of Science ®Google Scholar
• Saborit-Villarroya I, Vaisitti T, Rossi D, et al. (2011). E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia. Leukemia, 25, 479–88
   PubMed Web of Science ®Google Scholar
• Seymour JF, Talpaz M, Cabanillas F, et al. (1995). Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J. Clin Oncol, 13, 575–82
   PubMed Web of Science ®Google Scholar
• Skibola CF, Curry JD, Nieters A. (2007). Genetic susceptibility to lymphoma. Haematologica, 92, 960–9
   PubMed Web of Science ®Google Scholar
• Stasi R, Conforti M, Del Poeta G, et al. (1992). Soluble factors levels in the initial staging of high-grade non-Hodgkin’s lymphomas. Haematologica, 77, 518–21
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Masi M, et al. (1993). Antiphospholipid antibodies: Prevalence, clinical significance and correlation to cytokine levels in acute myelogenous leukemia and non-Hodgkin’s lymphoma. Thromb Haemost, 70, 568–72
   PubMed Web of Science ®Google Scholar
• Stewart BH, Hoskin DW. (1997). Regulatory role of CD8 in major histocompatibility complex-unrestricted tumoricidal activity of mouse T cells activated with anti-CD3 monoclonal antibody. Immunol Invest, 26, 601–14
   PubMed Web of Science ®Google Scholar
• Terry CF, Loukaci V, Green FR. (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem, 275, 1813–44
   Google Scholar
• Tsimberidou AM, Keating MJ. (2005). Richter syndrome: Biology, incidence, and therapeutic strategies. Cancer, 103, 216–28
   PubMed Web of Science ®Google Scholar
• Van Sinck J. (1990). Interleukin-6: An overview. Annu Rev Immunol, 8, 253–78
   Google Scholar
• Xin W, Rong Z, Xia G, et al. (2011). Clinical research plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance. J South Med Univ, 31, 1360–4
   Google Scholar
• Yee C, Sutcliffe S, Messner HA, Minden MD. (1992). Interleukin- 6 levels in the plasma of patients with lymphoma. Leuk Lymphoma, 7, 123–9
   PubMed Web of Science ®Google Scholar